International Pediatric Adrenocortical Tumor Registry

This study is currently recruiting participants.
Verified October 2013 by St. Jude Children's Research Hospital
Sponsor:
Information provided by (Responsible Party):
St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier:
NCT00700414
First received: June 13, 2008
Last updated: October 10, 2013
Last verified: October 2013
  Purpose

This study aims to collect demographic and medical information including detailed family history of cancer of children and adolescents with adrenocortical tumors in order to learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients with this rare disease, worldwide. In addition, investigators at St. Jude Children's Hospital plan to perform molecular studies of tumor cells aimed to clarify the role of the P53 gene and other genetic pathways in these tumors.


Condition
Adrenocortical Tumor

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: International Pediatric Adrenocortical Tumor Registry

Resource links provided by NLM:


Further study details as provided by St. Jude Children's Research Hospital:

Primary Outcome Measures:
  • Collect demographic/medical information, detailed family history of cancer of children/adolescents with adrenocortical tumors, learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients [ Time Frame: Indefinite ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Peripheral blood sample with DNA and RNA; Tumor Tissue (of any histology); Adrenocortical tumors;


Estimated Enrollment: 9999
Study Start Date: May 2001
Estimated Study Completion Date: December 2040
Estimated Primary Completion Date: December 2040 (Final data collection date for primary outcome measure)

Detailed Description:

Adrenocortical tumors (ACT) are very rare in children and teenagers. Of all the new cases of cancer diagnosed each year in the United States and Europe in patients younger than 20 years old, only about 0.2% are ACT. Studies from several laboratories including St. Jude Children's Research Hospital have revealed that the majority of children with ACT, particularly those younger than 4 years of age, have constitutional P53 mutations. Some mutations, as exemplified by the R337H P53 germline mutation, in which the function of the mutant protein is relatively preserved, the history of cancer in the carriers and their families is relatively unremarkable. In other cases, the P53 mutated gene encodes a functionally-impaired protein that predicts for a pervasive history of familial cancer (Li-Fraumeni syndrome). Therefore, these observations have implications for genetic counseling of families with childhood ACT and underscore the importance of genotype-phenotype correlations in familial cancer syndromes.

The creation of a specific rare tumor registry provides a mechanism to collect information that cannot be gathered in a single institution. The analysis of the registry data would permit an overview of the clinical, epidemiological, current treatment standards, and survival data of these patients and thus create opportunities for research. It also may facilitate the development of treatment consensus among investigators who register their patients and help to design future studies. Moreover, the combined COG and IPACTR studies are expected to provide meaningful insight into the biology of ACT, including clinical phenotype/genotype relationships, treatment outcome and long-term follow-up data in subjects with this rare tumor. Finally, it would provide data on the long-term consequences of exposure to tumor-secreted androgens (found in more than 80% of the pediatric cases) on children's growth and development.

  Eligibility

Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Age ≤ 21 years old at diagnosis of adrenocortical tumor Relatives of the ACT patients of any age with a diagnosis of malignant tumor

Criteria

Inclusion Criteria (patients):

  • Age ≤ 21 years old at diagnosis
  • Diagnosis of adrenocortical tumor (adenoma, carcinoma or undefined histology).
  • Signed informed consent

Exclusion Criteria (patients):

  • Age >21 years old at diagnosis
  • Informed consent has not been signed

Parents/Relatives Inclusion Criteria

  • Any age
  • Diagnosis of malignant tumor
  • Signed informed consent

Parents/Relatives Exclusion Criterion

  • Informed consent has not been signed
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00700414

Contacts
Contact: Raul C Ribeiro, MD 1-866-278-5833 info@stjude.org

Locations
United States, California
Stanford University Completed
Stanford, California, United States, 94305
United States, Florida
All Children's Hospital/St. Petersburg Hospital Recruiting
St. Petersburg, Florida, United States, 33701
Contact: Gregory Hale, MD         
Contact: Mike Gates, RN         
Principal Investigator: Gregory Hale, MD         
United States, Ohio
The Children's Medical Center Recruiting
Dayton, Ohio, United States, 45404
Contact: Mukund Dole, MD         
Contact: Jenny Dillon, RN, CCRP         
Principal Investigator: Mukund Dole, MD         
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Raul C Ribeiro, MD    866-278-5833    info@stjude.org   
Principal Investigator: Raul C Ribeiro, MD         
United States, Texas
Cook Children's Medical Center Recruiting
Fort Worth, Texas, United States, 76104
Contact: Meaghan Granger, MD         
Contact: Kathy Contreras         
Principal Investigator: Meaghan Granger, MD         
Sponsors and Collaborators
St. Jude Children's Research Hospital
Investigators
Principal Investigator: Raul C Ribeiro, MD St. Jude Children's Research Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier: NCT00700414     History of Changes
Other Study ID Numbers: IPACTR
Study First Received: June 13, 2008
Last Updated: October 10, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Adrenal Cortex Neoplasms
Adrenal Gland Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Adrenal Cortex Diseases
Adrenal Gland Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on April 16, 2014